On the eve of a trial with a former employee turned whistleblower, biotechnology company Biogen agreed to pay $900 million to settle allegations of lavishly overpaying doctors to prescribe their drugs to Multiple Sclerosis patients. | Poal: Say what you want.

Welcome • User Guide
ToS • Privacy • Canary
Donate • Bugs • License

©2026 Poal.co

502

•

On the eve of a trial with a former employee turned whistleblower, biotechnology company Biogen agreed to pay $900 million to settle allegations of lavishly overpaying doctors to prescribe their drugs to Multiple Sclerosis patients. (www.natlawreview.com)

(post is archived)

You are currently inside a comment thread.

Click here to see all the comments (4).

[–] • 1 pt

Selenium cures MS. It is a mineral deficiency.

link